New Jersey-based Seqirus today announced a new vaccine research and development facility will open in Massachusetts supporting the company's focus on a self-amplifying messenger RNA (sa-mRNA) technology platform, the next generation of mRNA technology. The new Waltham facility is expected to be fully operational by mid-2022.